Story Stocks^®

Hims & Hers Health (HIMS) is lower after a mixed Q2 in which strong revenue growth, subscriber gains, and a substantially higher sales outlook were overshadowed by a large earnings miss and significant margin compression. The negative reaction reflects concern about the profitability and cash-flow implications of HIMS' evolving weight-loss strategy even as the business continues to scale rapidly.

• Revenue increased 38% yr/yr to $753 mln as subscribers grew 19% to nearly 2.9 mln, while monthly revenue per average subscriber increased 21% to $92. The combination shows HIMS is expanding both its customer base and monetization, although the Eucalyptus acquisition contributed materially to international growth.
• Management guided Q3 revenue to $880-900 mln, well above the $792 mln consensus, and raised FY26 revenue guidance to $3.10-3.30 bln from $2.80-3.00 bln. However, the higher outlook incorporates Eucalyptus, complicating direct comparisons with consensus estimates that may not fully reflect the acquisition.
• Gross margin contracted sharply to 64% from 76% a year ago, reflecting the changing weight-loss product mix, including greater exposure to lower-margin branded GLP-1 medications. This compression represents a key concern as HIMS balances rapid expansion with the economics of its evolving weight-loss offering.
• Adjusted EBITDA declined to $60.3 mln from $82.2 mln, with margin falling to roughly 8% from 15%, while free cash flow was negative $68.2 mln. The GAAP loss also included sizable legal contingencies and acquisition-related expenses, meaning the EPS shortfall overstates the deterioration in underlying operations, but cash conversion remains an important watchpoint.
• FY26 adjusted EBITDA guidance was narrowed to $275-325 mln from $275-350 mln, leaving the low end unchanged while cutting the high end by $25 mln. That reduction alongside substantially higher revenue guidance indicates that incremental sales are currently carrying weaker profitability than investors had anticipated.

Briefing.com Analyst Insight

The central issue emerging from Q2 is no longer whether HIMS can generate strong growth, but how profitably it can convert that growth as its business mix evolves. Subscriber growth, rising revenue per subscriber, and the higher FY26 sales outlook demonstrate continued demand, while Eucalyptus adds another avenue for geographic expansion. However, the 1,200-bp yr/yr gross-margin contraction, lower adjusted EBITDA, and negative free cash flow illustrate the financial trade-offs accompanying the shift toward branded GLP-1s and continued investment in new products and markets. The sizable gap between accelerating revenue expectations and the reduced upper end of EBITDA guidance makes margin progression particularly important over the next several quarters. HIMS' next challenge is demonstrating that its expanding scale and broader healthcare platform can eventually produce stronger incremental margins and more consistent free cash flow.